• Learning Objective 1: Participants will be able to identify the prognostic factors that differentiate between benign and aggressive MS
  • Learning Objective 2: Participants will know the mechanisms of action, risks and benefits of different MS disease modifying agents
  • Learning Objective 3: Participants will be able to decide when to choose between inducation and escalation therapy.


Session date: 
01/14/2020 - 8:00am to 9:00am CST
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Susan Rubin, MD